Shire head not fazed by Sanofi-Genzyme talk; Teva must divest products for E.U. deal nod;

 @FiercePharma: Sources: Merck KGaA looking to sell infertility business. Article  | Follow @FiercePharma

>  Sanofi-Aventis' takeover of Genzyme would not upset the high-margin market in drugs for rare diseases, given the specialized nature of the business, Shire's chief executive says. Story

> Teva Pharmaceutical Industries has won E.U. approval for its buyout of German generics maker Ratiopharm, provided the companies sell off products in Netherlands and Hungary. Item

> Health Canada and Wyeth Canada are warning that the constipation drug Relistor puts patients at a higher risk of gastrointestinal perforation, especially if they have conditions that weaken the gastrointestinal wall. Report

> India's Lupin has appointed Paul McGarty, former CEO of U.S.-based Nycomed, as president of its U.S. subsidiary. Article

> Daiichi Sankyo says it would go ahead with a planned $17 million bid for 20 percent of Indian generics maker Zenotech Laboratories after the Indian Supreme Court approved the deal. News

> Unichem Laboratories, an Indian maker of antibiotics and pain killers, advanced as much as 4.6 percent in Mumbai trading after saying it may acquire companies or brands to expand its product range. Report

> Gedeon Richter rallied to its highest in almost four years after the largest drugmaker in Hungary said its second-quarter profit more than quadrupled on rising U.S. and Russian sales, exceeding analysts' estimates. News

Biotech News

 @FierceBiotech: Shire forges $565M buyout deal for Movetis. Story | Follow @FierceBiotech

 @JohnCFierce: BrainCells gets a depression drug from Proximagen for up to $51M, no breakout on the upfront (which is weak). News | Follow @JohnCFierce

> Early-stage deals are getting a lot sweeter for biotechs. Story

> Pfizer talks deal strategy as analysts buzz about Sanofi's next move. News

> CMP Therapeutics names Neill Moray Mackenzie CEO. Report

> Horizon Pharma braves a chilly market with $86 million IPO. Item

> BrainCells grabs neuropsych therapy in $51M licensing pact. Article

> Cypress Bio slashes staff and dumps co-promo deal. Report

> Isis, Genzyme upbeat on PhIII mipomersen data. Story

Medical Device News

 @FierceMedDev: Why the medical device drought in Kansas City? According to some: venture capital. Report | Follow @FierceMedDev

> EnteroMedics gets conditional OK for obesity study. Report

> PerkinElmer buys imaging firm VisMed. News

> Authors: Withdrawing LVAD support permissible. Report

> FDA plans to revamp 510(k) guidelines. Article

Drug Delivery News

> Bee venom can tell tumors to buzz off. Story

> Marina Biotech acquires RNAi delivery technology. Item

> Argenta gets $2.1M to improve drug delivery for animals. Article

> Nanoparticles just big enough to safely deliver cancer drug. News

And Finally... Researchers found a new mechanism that explains how certain immune cells are activated to create pathological antibodies, such as those found in autoimmune diseases like lupus and rheumatoid arthritis. Story

Suggested Articles

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.

Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.